Business
Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel
IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission
About this update from Tarsus Pharmaceuticals, Inc.
[{"type":"text","content":"IRVINE, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), a late clinical-stage biopharmaceutical company whose mission is to discover and deliver breakthrough treatments to transform the lives of patients with common and poorly treated diseases, starting with the eye, today announced the appointment of Bryan Wahl, MD, JD to the position of General Counsel. Dr. Wahl brings over 15 years of broad legal experience, including significant intellectual property (IP), corporate, and transactional expertise, to the position. In this role, he will provide strategic direction as Tarsus expands its innovative product pipeline, beginning with TP-03 for the potential treatment of Demodex blepharitis. Most recently, Dr. Wahl was a Partner at Knobbe Martens LLP in Orange County, where he focused on intellectual property protection, infringement studies, and due diligence for financings and strategic transactions, specifically with respect to pharmaceutical, biotechnology, and medical device companies. In this role, Dr. Wahl counseled clients from the pre-Series A stage through exit, including Tarsus, which has been one of his clients since shortly after it was founded. Dr. Wahl has received numerous accolades and recognition for his work at the firm. In addition to his law practice, Dr. Wahl has practiced inpatient internal medicine since 2002, most recently as a per diem hospitalist with Kaiser Permanente, caring for patients both on hospital wards and in the ICU. “Since its founding, Tarsus has pursued meaningful innovation to address unmet patient needs,” said Bobak Azamian, MD, PhD, CEO, Tarsus Pharmaceuticals, Inc. “As we continue to make our vision a reality, we are thrilled to welcome Bryan in the role of General Counsel. His unique combination of legal and medical expertise and breadth of corporate legal experience in strategic transactions and intellectual property will be invaluable to our leadership team as we discover and develop transformational new assets, both in eye care and other therapeutic areas.” Prior to joining Knobbe Martens, Dr. Wahl entered medical school after one undergraduate year, and received his medical degree with honors from the University of Hawaii John A. Burns School of Medicine in 1999. He completed an internal medicine residency in the UCLA-affiliated Cedars-Sinai Medi...